ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) — Recruiting • Phase III • NCT07742735.
- Apraglutide versus placebo for short bowel syndrome: 24-week trial testing effectiveness and safety in 124 patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase 3 placebo-controlled study is planned to further investigate the efficacy, safety, and tolerability of apraglutide in the overall SBS-IF (short bowel syndrome associated with intestinal failure) population during 24 weeks of study treatment. It is expected that approximately 124 participants will be randomized worldwide to either apraglutide or placebo in a 1:1 ratio in this trial. Conditions: Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF) Interventions: Apraglutide, Placebo Lead Sponsor: VectivBio AG Planned Enrollment: 124 participants